<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112078">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01644240</url>
  </required_header>
  <id_info>
    <org_study_id>0095</org_study_id>
    <nct_id>NCT01644240</nct_id>
  </id_info>
  <brief_title>A Phase 1, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the
      safety, tolerability, and pharmacokinetics (PK) of repeated IV doses of TD-8954 in healthy
      adults 18 to 45 years of age and healthy elderly subjects 65 to 85 years old. A healthy
      elderly subject population is included to evaluate the safety, tolerability, and PK of
      TD-8954 IV. Pharmacodynamic effects on bowel movements will also be evaluated. Screening for
      all cohorts will be conducted within 21 days before the first dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic measures</measure>
    <time_frame>1 week</time_frame>
    <description>Plasma Cmax, Tmax, t½, AUC0-24, AUC0-∞, AUCtau, Vss, and CL; urine Aetau, fe, CLr</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Gastrointestinal Motility Disorder</condition>
  <arm_group>
    <arm_group_label>TD-8954 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-8954 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-8954 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-8954 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-8954</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>TD-8954 Dose 1</arm_group_label>
    <arm_group_label>TD-8954 Dose 2</arm_group_label>
    <arm_group_label>TD-8954 Dose 3</arm_group_label>
    <arm_group_label>TD-8954 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - saline</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. For Cohorts 1: adult males and females age 18 to 45 years, inclusive; for Cohorts 2
             and 3, adult males and females 65 to 85 years of age, inclusive; for Cohort 4, adult
             males and females 18 to 45 or 65 to 85 years of age, inclusive.

          2. Body mass index (BMI)between 18 to 36 kg/m2, inclusive.

          3. Average frequency of ≥ 3 bowel movements per week.

        Exclusion Criteria:

          1. Persistent symptoms of functional GI disorder (such as irritable bowel syndrome,
             functional constipation, functional dyspepsia, or other symptom-based GI disorders
             unexplained by a pathologically based disorder) during the 6 months prior to
             screening, including a history of major surgery of the GI tract, excluding
             cholecystectomy and appendectomy.

          2. History or presence of clinically significant respiratory, GI, renal, hepatic,
             endocrine, hematological, neurological (including chronic headache, current or prior
             psychiatric disease/condition, stroke), cardiovascular, psychiatric, musculoskeletal,
             genitourinary, immunological, or dermatological disorders. Subjects with mild,
             chronic, stable disease (e.g., controlled hypertension, controlled
             hypercholesterolemia, non insulin-dependent diabetes, osteoarthritis) may be enrolled
             if the condition is well controlled and not anticipated to interfere with the
             objectives of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 1, 2014</lastchanged_date>
  <firstreceived_date>July 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
